Research Scientist - Nucleic Acids Chemistry R&D
About the job
- A PhD in organic chemistry, with extensive training and practical laboratory experience in organic synthesis, physical organic chemistry, and bioorganic chemistry.
- Experience with nucleoside, nucleotide, and solid-phase oligonucleotide synthesis.
- Experience preparing fluorescent dye conjugates of nucleotides and oligonucleotides.
- Proficiency in instrumental chemical analysis methods such as nuclear magnetic resonance (NMR), high-performance liquid chromatography (HPLC), mass spectrometry (MS), and Fourier-transform infrared spectroscopy (FTIR).
- Ability to plan and execute independent and collaborative research projects.
- Co-authorship on one or more publications in peer-reviewed scientific journals.
- Ability to develop additional competencies and apply practical skills and knowledge to solving applied scientific and technical problems.
- Plan and execute applied research experiments involving synthesis, modification, and characterization of modified nucleotides, nucleoside polyphosphates, and oligonucleotides.
- Prepare fluorescent dye conjugates of nucleotides and oligonucleotides.
- Modify and characterize materials for solid-phase synthesis.
- Collaborate with and/or supervise other scientists and engineers on joint projects.
- Document experimental work; analyze data; and document and present results.
- Prepare written methods and standard operating procedures (SOPs).
- Operate and maintain laboratory and analytical equipment.
- Support research and development (R&D), pilot manufacturing operations, and quality control (QC).
- Working knowledge and practical experience with polymer and surface chemistry.
About the company
Centrillion Technologies develops tools for genomic studies, including sequencing, bioinformatics, and a new generation of DNA chips designed for high-density, high-quality probes that work with sequencing. Its products include ATOM, a high-throughput detection system, and VirusHunter MVP, a pathogen-detection assay, along with sequencing and droplet digital PCR services for researchers and drug discovery groups. It differentiates itself by offering integrated genomics hardware, assays, and services with DNA chips optimized for large-scale analysis that complement sequencing workflows. Its goal is to enable broad, scalable genomic studies to accelerate drug discovery, personalized medicine, and molecular diagnostics.
Company Size
51-200
Company Stage
Series B
Total Funding
$24.3M
Headquarters
Palo Alto, California
Founded
2009
Get referred to Centrillion Technologies
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 2026 site updates show active product marketing and service availability.
- Centrillion’s August 2026 AI messaging targets genome, cell, and tissue data buyers.
- The platform keeps multiple revenue paths: research chips, diagnostics, and sequencing services.
What critics are saying
- VirusHunter MVP remains only through Molecular Vision Laboratories as of August 2026.
- Centrillion shows no fresh 2025-2026 financing, suggesting constrained commercial scale.
- Illumina, Thermo Fisher, and Oxford Nanopore can crush adoption if chip volumes lag.
What makes Centrillion Technologies unique
- Centrillion’s September 2026 chips combine 50,000-2 million variants with sequencing workflows.
- VirusHunter pairs pathogen detection and whole-genome sequencing on ATOM and QuadCore chips.
- The company still owns a rare integrated stack: chips, assays, and clinical-lab services.
Help us improve and share your feedback! Did you find this helpful?